Teva Pharmaceutical Industries Ltd. TEVA
We’re very interested in TEVA as a potential bottom bounce play. The stock registered new 52-week lows midway through last week, and has exhibited a solid level of support. Trending up slightly in the premarket, we’re going to be tracking a pair of June options contracts to coincide with what could easily be a significant rebound.
Our specific targets are going to be the TEVA 06/28 $12.50 & $13 Calls, which could present us with sizable opportunities to profit
Sprint Corp. S
We’re also going to set our sights on a range of Sprint options as the company attempts to gain FCC and DOJ approval on its $26B proposed merger with T-Mobile. The review period ends in June, but we’re more interested in the short term capability of the stock to provide us with quick strike chances. We’re going to radar the S Weekly $7-8 Calls.
Adverum Biotechnologies, Inc. ADVM – Review
A stock we recently began tracking, ADVM has been in a fairly continual uptrend since we signaled it for observation on the morning of April 17th. In the last month, the stock has made considerable bullish strides.
From the low we observed on the day of our initial alert, at 5.44, ADVM has gone on to record a high of 9.17. That comes out to an increase of 69%
TOPS, GERN, GMO, AMRH, TRQ, CREX, FUN, ICON, SQQQ, TMUS, INDY